Announcements Trials
Browse Landscape

Phase

Phase 1 16Phase 2 9Phase 1/2 6Phase 3 1

Status

Terminated 4Unknown 1Active not recruiting 1

Sponsor Class

INDUSTRY 5OTHER 1

Study Type

Interventional 6

Sponsor

Cancer Type

Gastrointestinal 60Head & Neck 36Thoracic 27Tumor-Agnostic 6CNS 6Genitourinary 5Sarcoma 3Breast 3Other solid neoplasm 2Gynecologic 2Dermatologic 2Myeloid 1

Conditions

Neoplasms 3Neoplasm Metastasis 2Carcinoma, Squamous Cell 2

Interventions

pembrolizumab 18Nivolumab 18Gemcitabine 9Ipilimumab 8Cisplatin 8Carboplatin 8Capecitabine 8Paclitaxel 6Cetuximab 6atezolizumab 5Irinotecan 5Docetaxel 5Cyclophosphamide 5Bevacizumab 5avelumab 4Trastuzumab 4Fluorouracil 4trametinib 3spartalizumab 3Specimen Handling 3Pemetrexed 3Leucovorin 3Everolimus 3Dexamethasone 3Biopsy 3urelumab 2toripalimab 2tislelizumab 2ribociclib 2repotrectinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 1/2 × Cetuximab × Tumor-Agnostic × Clear all
NCT04009681 2025-12-15

HAMMER

Synthorx, Inc, a Sanofi company

Phase 1/2 Terminated
175 enrolled
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT04717375 2025-08-07

Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors

Sanofi

Phase 1/2 Terminated
125 enrolled
Tumor-Agnostic

Neoplasms

NCT02671435 2025-07-22

A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors

MedImmune LLC

Phase 1/2 Active not recruiting
383 enrolled 48 charts
Tumor-Agnostic

Neoplasm Metastasis

NCT03387111 2024-08-05

QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed

ImmunityBio, Inc.

Phase 1/2 Terminated
4 enrolled 14 charts
Tumor-Agnostic

Carcinoma, Squamous Cell

NCT00954512 2018-08-24

Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)

Merck Sharp & Dohme LLC

Phase 1/2 Terminated
15 enrolled 11 charts
Tumor-Agnostic

Neoplasms

NCT01760811 2013-01-04

CETUXIMAB Given for 3 Weeks as Neoadjuvant Treatment in Locally Advanced Tongue Cancer ; A NEW PARADIGM OF TREATMENT

Rabin Medical Center

Phase 1/2 Unknown
25 enrolled
Tumor-Agnostic

Carcinoma, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡